Baigrie D, Nookala V (2022) Bullous pemphigoid. StatPearls. Treasure Island (FL)

Schmidt E, Della Torre R, Borradori L (2012) Clinical features and practical diagnosis of bullous pemphigoid. Immunol Allergy Clin 32(2):217–232

Google Scholar 

Endo M, Watanabe Y, Yamamoto M, Igari S, Kikuchi N, Yamamoto T (2021) Erythrodermic bullous pemphigoid. Dermatol Sin 39(1):61–62. https://doi.org/10.4103/ds.ds_45_20

Article  Google Scholar 

Bernard P, Antonicelli F (2017) Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol 18(4):513–528. https://doi.org/10.1007/s40257-017-0264-2

Article  PubMed  Google Scholar 

Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI (2017) Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol 176(1):87–99.https://doi.org/10.1111/bjd.14821

Chen Y, Wu C, Lin M, Chen T, Liao K, Chen Y et al (2011) Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 165(3):593–599

Article  CAS  PubMed  Google Scholar 

Langan SM, Groves RW, West J (2011) The relationship between neurological disease and bullous pemphigoid: a population-based case–control study. J Invest Dermatol 131(3):631–636

Article  CAS  PubMed  Google Scholar 

Zeng FA, Wilson A, Sheriff T, Murrell DF (2022) Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: a systematic review. JAAD international 9:33–43

Article  PubMed  PubMed Central  Google Scholar 

Cole C, Borradori L, Amber KT (2022) Deciphering the contribution of BP230 autoantibodies in bullous pemphigoid. Antibodies 11(3):44

Article  CAS  PubMed  PubMed Central  Google Scholar 

Charneux J, Lorin J, Vitry F, Antonicelli F, Reguiai Z, Barbe C et al (2011) Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 147(3):286–291

Article  PubMed  Google Scholar 

Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P et al (2004) BP230-and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 122(6):1413–1422

Article  CAS  PubMed  Google Scholar 

Yoshida M, Hamada T, Amagai M, Hashimoto K, Uehara R, Yamaguchi K et al (2006) Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 41(1):21–30

Article  CAS  PubMed  Google Scholar 

Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K et al (1996) A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci 93(16):8569–8571

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schiavo AL, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R (2013) Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 31(4):391–399

Article  PubMed  Google Scholar 

Arakawa M, Dainichi T, Ishii N, Hamada T, Karashima T, Nakama T et al (2011) Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol 20(12):1022–1024

Article  CAS  PubMed  Google Scholar 

Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G (2020) Bullous pemphigoid: trigger and predisposing factors. Biomolecules 10(10):1432

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin J-D, Hung S-J (2021) Radiation-induced bullous pemphigoid in a patient with Kaposi’s sarcoma. Dermatol Sin 39(3):159–160. https://doi.org/10.4103/ds.ds_23_21

Article  Google Scholar 

Chao Y-C, Liu K-L (2022) New-onset bullous pemphigoid triggered by AstraZeneca COVID-19 vaccine. Dermatol Sin 40(4):245–246. https://doi.org/10.4103/1027-8117.358000

Article  Google Scholar 

Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV (2019) New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol 10:1506

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hiroyasu S, Turner CT, Richardson KC, Granville DJ (2019) Proteases in pemphigoid diseases Front Immunol 10:1454. https://doi.org/10.3389/fimmu.2019.01454

Article  CAS  PubMed  Google Scholar 

Ellebrecht CT, Maseda D, Payne AS (2022) Pemphigus and pemphigoid: from disease mechanisms to druggable pathways. J Invest Dermatol 142(3 Pt B):907–914.https://doi.org/10.1016/j.jid.2021.04.040

Cole C, Vinay K, Borradori L, Amber KT (2022) Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms. Front Immunol 13:912876. https://doi.org/10.3389/fimmu.2022.912876

Article  CAS  PubMed  PubMed Central  Google Scholar 

Messingham KA, Noe MH, Chapman MA, Giudice GJ, Fairley JA (2009) A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 346(1–2):18–25

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N et al (2008) Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 49(2):153–161

Article  CAS  PubMed  Google Scholar 

Mihai S, Chiriac MT, Herrero-González JE, Goodall M, Jefferis R, Savage CO et al (2007) IgG4 autoantibodies induce dermal–epidermal separation. J Cell Mol Med 11(5):1117–1128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernard P, Reguiai Z, Tancrede-Bohin E, Cordel N, Plantin P, Pauwels C et al (2009) Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 145(5):537–542. https://doi.org/10.1001/archdermatol.2009.53

Article  PubMed  Google Scholar 

Kalowska M, Ciepiela O, Kowalewski C, Demkow U, Schwartz RA, Wozniak K (2016) Enzyme-linked immunoassay index for anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid. Acta Derm Venereol 96(2):191–196. https://doi.org/10.2340/00015555-2101

Article  CAS  PubMed  Google Scholar 

Zhou XP, Liu B, Xu Q, Yang Y, He CX, Zuo YG et al (2016) Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis. J Dermatol 43(2):141–148. https://doi.org/10.1111/1346-8138.13051

Article  CAS  PubMed  Google Scholar 

Asbrink E, Hovmark A (1984) Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies. Acta Derm Venereol 64(3):243–246

Article  CAS  PubMed  Google Scholar 

D’auria L, Pietravalle M, Mastroianni A, Ferraro C, Mussi A, Bonifati C et al (1998) IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch Dermatol Res 290(1–2):25–27

Article  PubMed  Google Scholar 

Ma L, Wang M, Wang X, Chen X, Zhu X (2015) Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients. J Dermatol Sci 78(1):76–77

Article  CAS  PubMed  Google Scholar 

Hiroyasu S, Barit JJG, Hiroyasu A, Tsuruta D (2022) Pruritogens in pemphigoid diseases: possible therapeutic targets for a burdensome symptom. J Dermatol. https://doi.org/10.1111/1346-8138.16652

Article  PubMed  PubMed Central  Google Scholar 

van Beek N, Luttmann N, Huebner F, Recke A, Karl I, Schulze FS et al (2017) Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 153(1):30–38. https://doi.org/10.1001/jamadermatol.2016.3357

Article  PubMed  Google Scholar 

Chiorean RM, Baican A, Mustafa MB, Lischka A, Leucuta DC, Feldrihan V et al (2018) Complement-activating capacity of autoantibodies correlates with disease activity in bullous pemphigoid patients. Front Immunol 9:2687. https://doi.org/10.3389/fimmu.2018.02687

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL et al (1995) The role of complement in experimental bullous pemphigoid. J Clin Invest 95(4):1539–1544. https://doi.org/10.1172/JCI117826

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Ujiie H, Shibaki A, Wang G, Moriuchi R, Qiao HJ et al (2010) Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 185(12):7746–7755. https://doi.org/10.4049/jimmunol.1000667

Article  CAS  PubMed  Google Scholar 

Karsten CM, Beckmann T, Holtsche MM, Tillmann J, Tofern S, Schulze FS et al (2018) Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2. Front Immunol 9:488

Article  PubMed  PubMed Central  Google Scholar